BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$8.80
arrow_downward
-2.87%(-0.26) 1D
$8.81
arrow_upward
+0.05% (+0.0045)bedtimeAfter hours
Closed: Sep 9, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$9.07
High
$9.23
Low
$8.80
Mkt. cap
2.25B
Avg. vol.
3.27M
Volume
0.00
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.57
Shares outstanding
255.54M
No. of employees
435
Open
$9.07
High
$9.23
Low
$8.80
Mkt. cap
2.25B
Avg. vol.
3.27M
Volume
0.00
52-wk high
$11.22
52-wk low
$6.00
EPS
-$1.50
Beta
0.57
Shares outstanding
255.54M
No. of employees
435
News stories
From web sources and news partners
GuruFocus
·
14 hours ago
BCRX Looks 24.9% Undervalued on GF Valueâ„¢ Despite Unprofitabilit
Yahoo Finance
·
1 day ago
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease
Investing.com
·
1 day ago
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com